Gatifloxacin appears to be both safe and highly effective in treating acute and recurrent otitis media in children, and is not associated with either acute or long-term joint disorders, Michael Pichichero, M.D., and his colleagues reported.

In the compilation of four trials (two phase II and two phase III), they also concluded that the drug, a fluoroquinolone, was more effective in eradicating middle ear pathogens than was amoxicillin/clavulanate.

The effect of a 10-day course of gatifloxacin (10 mg/kg per day) was evaluated in 867 children aged 6 months to 7 years. The phase III trials also included 109 children who received amoxicillin/clavulanate as a comparator. All children had acute otitis media (OM), recurrent OM, or OM treatment failure (Clin. Infect. Dis. 2005;41:470-8).

In the phase II trials (414 children), the high rate of discontinuation (8%) was primarily due to vomiting because of the bitter taste of an early formulation of the drug, said Dr. Pichichero of the University of Rochester (N.Y.) and his co-investigators. In the phase III studies, with a new formulation, the rate of discontinuation was similar in both groups (2%).

Transient arthralgia occurred in 12 (1.4%) of the 867 children. There were no abnormal imaging studies in any of the seven who were examined by an orthopedist. One child discontinued therapy due to knee swelling and abnormal gait; no joint abnormalities were seen on imaging. In the phase III studies, the rate of arthralgia was similar between the gatifloxacin and amoxicillin/clavulanate groups (1.5% and 1.3%).

One-year safety data was available for 671 gatifloxacin-treated children. There was no evidence of arthropathy in any. A 4-year-old girl treated with the study drug developed Achilles tendon pain, which resolved in 5 days with rest and ice.

Gatifloxacin was not associated with hepatotoxicity, clinically relevant hypoglycemia, phototoxicity, or central nervous system toxicity. The cure rate of the pooled phase II studies was 81%. In the first phase III study, the cure rate of gatifloxacin was 90%, compared with 84% for amoxicillin/clavulanate. The cure rate for gatifloxacin in the second phase II study was 85%, compared with 79% for amoxicillin/clavulanate.

The study drug was especially effective in children younger than 2 years with severe acute otitis media.

Supporting your pediatric vaccine needs every step of the way

To order Sanofi Pasteur Inc. pediatric vaccines, log on to www.vaccineshoppe.com or call 1-800-VACCINE (1-800-822-2463).

DAPTCAL (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) is a product of Sanofi Pasteur Inc. (formerly Aventis Pasteur Inc.) and distributed by Sanofi Pasteur Inc. (formerly Aventis Pasteur Inc.).

ActHIB (Haemophilus b Conjugate Vaccine (Tetanus Toad Conjugate)) is a product of Sanofi Pasteur Inc. (formerly Aventis Pasteur Inc.) and distributed by Sanofi Pasteur Inc. (formerly Aventis Pasteur Inc.).

IPOL (Poliomyelitis Vaccine Inactivated) and TRIHIBit (TriHIBit® (Diphteria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed)) are products of Sanofi Pasteur Inc. (formerly Aventis Pasteur Inc.) and distributed by Sanofi Pasteur Inc. (formerly Aventis Pasteur Inc.).

Before administering, please see full Prescribing Information for DAPTCAL, ActHIB, IPOL, TriHIBit, and TRIHIBi vaccine.

DAPTCAL vaccine is manufactured by Sanofi Pasteur Limited (formerly Aventis Pasteur Limited) and distributed by Sanofi Pasteur Inc. (formerly Aventis Pasteur Inc.) and IPOL vaccines are manufactured by Sanofi Pasteur SA (formerly Aventis Pasteur SA) and distributed by Sanofi Pasteur Inc. (formerly Aventis Pasteur Inc.).

TriHIBit and TRIHIB vaccines are manufactured and distributed by Sanofi Pasteur Inc.

©2005 Sanofi Pasteur Inc.